ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TROP2 Antibody-drug Conjugate ESG401

Its studies are mostly in Breast Neoplasms · Triple Negative Breast Neoplasms, led by 2 companies.

Drug pageAnti-TROP2 Antibody-drug Conjugate ESG401: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 22, 20243 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceuticalits history only22 open or runningphase 3since Apr 22, 2024Apr 22, 2024Jun 2027phase 3 · NCT06732323
Shanghai Escugen Biotechnologyits history only10 open or runningphase 2since May 13, 2021May 13, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2021First study: phase 2 study in Breast NeoplasmsNew to Shanghai Escugen BiotechnologyShanghai Escugen Biotechnology · NCT04892342 · 156 enrolled · China
  2. Apr 22, 2024Qilu Pharmaceutical’s first study: phase 3 study in Breast NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06383767 · 378 planned · China
  3. Dec 10, 2024Phase 3 study in Triple Negative Breast NeoplasmsQilu Pharmaceutical · NCT06732323 · 504 planned · China

Ahead

  1. Jun 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsQilu Pharmaceutical · NCT06732323
  2. Jun 30, 2027Primary completion: phase 3 study in Breast NeoplasmsQilu Pharmaceutical · NCT06383767

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of sacituzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06732323Triple Negative Breast Neoplasms · China3RecruitingQilu PharmaceuticalJun 2027504
NCT06383767Breast Neoplasms · China3RecruitingQilu PharmaceuticalJun 30, 2027378
NCT04892342Breast Neoplasms · China2CompletedShanghai Escugen BiotechnologyJun 30, 2025156

How it is read

Names in the registry

  • “ESG401”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.